FLAGSHIP 2
TRANSLATIONAL THERANOSTICS
FLAGSHIP LEADER
RESEARCH FELLOW
Find Dr Agarwal on ResearchGate
Dr Veenoo Agarwal ( current )
Dr David Chan ( former )
Prof Dale Bailey
RESEARCH ASSOCIATE
Dr Aimee Hayes ( former )
Sharon Gordon
GOAL
BRINGING NEW THERANOSTIC PAIRS INTO CLINICAL USE BY FACILITATING RAPID TRANSLATION FROM THE CLINICAL TESTING PHASE INTO CLINICAL TRIALS AND IMPROVING PATIENT OUTCOMES .
DIRECTION
TO IMPROVE AND INCREASE THE RANGE OF THERANOSTIC RADIONUCLIDE THERAPY TREATMENTS AVAILABLE AND TO OPTIMISE THEIR USE TO DELIVER IMPROVED PATIENT OUTCOMES .
“ Theranostics ” is the name given to an emerging methodology for imaging and delivering therapy with a single compound , usually a molecule , nanoparticle or a peptide ( or vector ). Usually , different labels are added to the vector for pre - therapeutic imaging and for therapy . Common examples of some of the labels used are radionuclides such as PET or SPECT imaging labels ( e . g ., Gallium - 68 , Technetium - 99m , Iodine - 124 , Copper - 64 ) and
and therapy with a beta particle emitting radionuclide ( e . g ., Iodine - 131 , Lutetium - 177 , Yttrium - 90 , Copper - 67 ). Other non - radionuclide labels that can be imaged are also available , such as fluorescent compounds . The imaging often serves to establish that the disease targeted by the therapy demonstrates sufficient uptake of the theranostic vector before proceeding with the treatment .
P A G E
1 4
Made with FlippingBook - professional solution for displaying marketing and sales documents online